📅 PUBMED DAILY TRIAGE — 2026-08-16 Window: 2026-08-15T00:00:00Z → 2026-08-16T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~112 across all topics | Candidates evaluated: 112 High priority: 7 | Standard: 27 | Low/archive: 0 | Unsolicited finds: 3 Run status: PARTIAL_SUCCESS (T2 CBC/ML — 0 relevant candidates in 24h + 48h window)
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
PMID-42603649 · The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer · 9/10 · 🟠 NOVEL_TREATMENT — First FDA-approved PROTAC ever; historic drug-modality milestone; Phase III VERITAC-2 demonstrated superior PFS over fulvestrant in ESR1-mutated endocrine-resistant breast cancer, validating targeted protein degradation as a clinical platform.
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
PMID-42602880 · GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk · 9/10 · 🟠 NOVEL_TREATMENT — Large EHR target-trial emulation (n=57,802 matched) demonstrating GLP-1 RAs associated with 54% lower incident Alzheimer's disease; semaglutide-specific signal reproduced (HR 0.46→0.56); cardiorenal pleiotropic benefits additive.
PMID-42603240 · Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis · 9/10 · 🟢 NEAR_TERM_IMPLEMENTABLE — Largest BP meta-analysis for these agents (32 RCTs, n=47,332); tirzepatide reduces hypertension risk 60% but doubles dose-dependent hypotension risk; semaglutide is BP-neutral. Directly actionable prescribing guidance.
Early cancer detection (liquid biopsy, ctDNA, cfDNA)
PMID-42602860 · Ultra-low-pass whole-genome sequencing of bile cfDNA in patients with biliary strictures · 9/10 · 🔴 EARLY_CANCER_DETECTION — Novel bile ULP-WGS detects biliary malignancy up to 100+ days before conventional cytology at first ERCP (n=95); 96% specificity; CCA vs PDAC discriminator (accuracy 0.864). Major unmet need.
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
PMID-42603588 · Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies · 8/10 · 🟠 NOVEL_TREATMENT — Prospective Phase II study (n=39) of azacitidine-primed reduced-intensity conditioning; OS 64%, PFS 54% at 1 year; pharmacodynamic DNA hypomethylation correlates with survival—epigenetic biomarker hypothesis for high-risk AML/MDS alloHCT.
Precision oncology and genomic medicine
PMID-42602967 · TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma · 8/10 · ⚪ PROMISING_PRELIMINARY — Genome-wide CRISPR-Cas9 + multi-omics screening in 167 MM patient samples establishes TP53 mutation (not del(17p)) as the driver of specific drug vulnerabilities including HDAC/HSP90 inhibitor sensitivity; challenges current classification.
Rare diseases with high unmet need
PMID-42603082 · Natural History and Treatment Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Retrospective Longitudinal Cohort Study · 8/10 · 🟡 UNDERSERVED_POPULATION — First large multinational natural history study of congenital TTP (n=78, 9 sites, 8.1-year follow-up); plasma prophylaxis reduces acute events but fails to prevent ongoing manifestations or organ damage; establishes real-world comparators for recombinant ADAMTS13 trials.
🟢⚪ STANDARD (5-7) — Top by Topic
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
- PMID-42603591 · TCI score-based conditioning intensity in cord blood transplantation for MDS (n=1127 registry) · 7/10 · Treatment Innovation
- PMID-42603590 · CAR-FIT fitness index for safe equitable CAR-T delivery in borderline DLBCL patients (n=80) · 7/10 · Treatment Innovation
- PMID-42602990 · TP53-mutated DLBCL therapeutic outcomes: systematic review meta-analysis (31 studies, n=1164) · 7/10 · Treatment Innovation
- PMID-42603134 · In vivo T-cell depletion + PK-based busulfan conditioning improving AML alloHCT outcomes · 6/10 · Treatment Innovation
- PMID-42603756 · SOHO state-of-art on mediastinal gray-zone lymphoma: novel biologic insights (NCI/Georgetown) · 5/10 · Treatment Innovation
CBC-based diagnostics and ML in hematology
No high-priority finds today (no relevant candidates in 24h or 48h window). T2 expansion logged.
Early cancer detection
No STANDARD finds (only 1 relevant candidate, scored HIGH).
AI/ML in clinical diagnostics and imaging
- PMID-42603762 · Deep learning multi-modal muscle ultrasound for neuromuscular disease screening (AUPRC=0.87, n=320) · 6/10 · Diagnostics
- PMID-42603074 · CT deep learning volumetric analysis for iNPH (AUC 0.97-0.99, 3 international external cohorts) · 6/10 · Diagnostics
- PMID-42601852 · AI automated Updated Sydney System grading for H. pylori gastric biopsies · 6/10 · Diagnostics
Precision oncology and genomic medicine
- PMID-42601904 · Dynamic ctDNA ESR1 mutation profiling in HR+/HER2- breast cancer: from biomarker to decision node (SERENA-6 56% progression risk reduction) · 7/10 · Genomics/Precision Medicine
- PMID-42603641 · DNA damage repair genes in lung cancer: diagnostic, prognostic, therapeutic review (INCan, Mexico City) · 6/10 · Genomics/Precision Medicine
- PMID-42602988 · Multi-omics FOXA1 cancer-type-specific transcriptional networks and functional risk variants · 6/10 · Genomics/Precision Medicine
- PMID-42601762 · PRISMA systematic review of pharmacogenetic anticancer clinical trials (ClinicalTrials.gov landscape) · 6/10 · Genomics/Precision Medicine
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
- PMID-42603482 · Pre-treatment T cell phospho-signalling identifies pembrolizumab response in NSCLC (n=64, HR=2.83) · 7/10 · Diagnostics + Treatment Innovation
- PMID-42603295 · Lactate-induced STING K370 lactylation as metabolic immune checkpoint; LDHA inhibition rescues in patient-derived glioblastoma models · 7/10 · Drug Development
- PMID-42602965 · Pan-cancer analysis: immunotherapy efficacy in SMARC-altered cancers (ORR 48% vs 16%, n=53) · 7/10 · Treatment Innovation
- PMID-42603642 · Lurbinectedin in SCLC: Phase III IMforte maintenance lurbinectedin + atezolizumab evidence review · 6/10 · Treatment Innovation
- PMID-42603344 · scRNA-seq identifies ICI-resistant LUAD subcluster; ARNTL2 validated as malignant driver (7 cohorts) · 6/10 · Genomics/Precision Medicine
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- PMID-42603595 · GLP-1R + CTR/AMYR co-agonism in lateral dorsal tegmental nucleus: additive food intake and weight reduction (preclinical) · 6/10 · Drug Development
- PMID-42602345 · Validation of pharmacist-led semaglutide prescribing algorithm for T2DM and obesity · 6/10 · Treatment Innovation
- PMID-42602911 · Personalizing HFrEF therapy: phenotype-based GDMT framework bridging evidence and practice · 5/10 · Treatment Innovation
- PMID-42602910 · GLP-1 RA + SGLT2i combination: additional cardiometabolic benefits review · 5/10 · Treatment Innovation
Aging, longevity, and population health
- PMID-42601976 · Urinary organophosphate (DETP) metabolites, DNA methylation aging, and heart disease mortality · 6/10 · Public Health
- PMID-42601837 · SASP-dependent paracrine senescence spreading between human brain cell types; druggable SASP targets · 6/10 · Drug Development
- PMID-42602551 · GDF15 as immunomodulatory multi-node hub in skin aging and inflammatory dermatoses; biomarker framework · 5/10 · Diagnostics
Rare diseases with high unmet need
No STANDARD finds today (only 1 case report scored LOW).
💡 UNSOLICITED FINDS
- PMID-42603618 · Preoperative SBRT for early-stage luminal breast cancer: systematic review meta-analysis PRELUMEN (11 prospective trials, n=428, pCR 21.4%); irradiation-to-surgery interval is dominant modifiable predictor (R²=98.9%) · 7/10 · ⚪ PROMISING_PRELIMINARY · Treatment Innovation
- PMID-42603309 · HPV self-collection nearly doubles cervical cancer screening participation in underserved Colombian communities (49% vs 26%); high follow-up compliance maintained (89.6%) · 7/10 · 🟡 UNDERSERVED_POPULATION · Early Detection + Public Health
- PMID-42603582 · Longitudinal automated lipid target monitoring integrated into laboratory clinical decision support system · 6/10 · Diagnostics + Public Health
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 14 articles
- Genomics/Precision Medicine: 7 articles
- Diagnostics: 7 articles
- Drug Development: 4 articles
- Early Detection: 2 articles
- Public Health: 3 articles (some dual-category)
By evidence maturity:
- Exploratory: 22
- Validated: 9
- Potentially Practice-Changing: 3
By watchlist topic (reviewed / kept in output / highest score):
| Topic | Reviewed | Kept | Highest Score |
|---|---|---|---|
| T1: Hematologic malignancies | 15 | 6 | 8 |
| T2: CBC/ML hematology | 1 | 0 | 0 (no relevant) |
| T3: Early cancer detection | 2 | 1 | 9 |
| T4: AI/ML diagnostics | 8 | 3 | 6 |
| T5: Precision oncology | 15 | 5 | 8 |
| T6: Novel therapeutics | 15 | 6 | 9 |
| T7: Cardiovascular-metabolic | 15 | 5+2 HIGH | 9 |
| T8: Aging/longevity | 13 | 3 | 6 |
| T9: Rare diseases | 2 | 1 | 8 |
| Sentinel (unsolicited) | 10 | 3 | 7 |
By source type: peer_reviewed: 34 | preprint: 0
Topics with zero 8+ articles this run:
- T2: CBC-based diagnostics and ML in hematology (0 relevant candidates)
- T4: AI/ML in clinical diagnostics and imaging (highest score: 6)
- T8: Aging, longevity, and population health (highest score: 6)
🔧 RUN NOTES
Window expansion (T2 triggered): CBC/ML hematology search returned 0 results on the 24h CRDT window. Expanded to 48h (2026/08/14-16): 1 result (PMID 42601395, "Fully-automated sleep staging for Parkinson's disease") — not relevant to CBC/ML hematology topic (false positive match). T2 = 0 relevant candidates this run. Window expansion logged per protocol.
T2 fallback query used: ("complete blood count"[tiab] OR CBC[tiab] OR "hematology analyzer"[tiab] OR ...) AND ("machine learning"[tiab] OR ...) NOT hemorrhage[tiab] NOT hematoma[tiab] with datetype=crdt, mindate=2026/08/14, maxdate=2026/08/16.
run_status=PARTIAL_SUCCESS: Due to T2 zero-result condition. All other 9 topics have complete PMID coverage with no missing PMIDs after retrieval.
Notable findings:
- 🏆 Historic milestone: First FDA-approved PROTAC (vepdegestrant/ARV-471) — highly significant for the targeted protein degradation drug class. Phase III evidence in ESR1-mutated breast cancer.
- ⚡ Major GLP-1 signal: Two independent HIGH-scoring articles on GLP-1 pleiotropic benefits — Alzheimer's disease risk reduction (54% lower incidence, n=57,802) and tirzepatide blood pressure hemodynamic differentiation (32 RCTs, n=47,332).
- 🔬 Bile cfDNA for biliary malignancy is an exciting early-detection application with 100+ day lead time over conventional diagnosis.
Cross-topic overlaps noted:
- PMID 42603076: T1 (hematologic) + T6 (novel therapeutics) — case report, scored LOW, excluded
- PMID 42602176: T7 (cardiometabolic) + T8 (aging) — review, primary assignment T7
- PMID 42603642: T6 (novel therapeutics) + Sentinel — watchlist match, unsolicited_find=False
Truncation: T1 (15/38), T6 (15/39), Sentinel (10/39) all hit their caps. Remaining results in each topic not reviewed this run.
Abstract retrieval: 93 unique PMIDs fetched via esummary; abstracts retrieved for 35 articles via efetch in 8 parallel batches; 5 articles classified from title/metadata (classification_confidence=medium) due to truncated or absent abstract text.
Attempt: 1 of 3 | Schema: v1.3